Immuno-Oncology beyond TILs: Unleashing TILCs

Olivier Demaria; Eric Vivier

doi:10.1016/j.ccell.2020.03.021

Immuno-Oncology beyond TILs: Unleashing TILCs

Cancer Cell. 2020 Apr 13;37(4):428-430. doi: 10.1016/j.ccell.2020.03.021.

Authors

Olivier Demaria¹, Eric Vivier²

Affiliations

¹ Innate Pharma Research Laboratories, Innate Pharma, Marseille, France. Electronic address: [email protected].
² Innate Pharma Research Laboratories, Innate Pharma, Marseille, France; Aix Marseille University, CNRS, INSERM, CIML, Marseille, France; APHM, Hôpital de la Timone, Service d'Immunologie, Marseille-Immunopôle, Marseille, France.

PMID: 32289267
DOI: 10.1016/j.ccell.2020.03.021

Abstract

Innate lymphoid cells (ILCs) are detected in multiple tumor types, but their contribution to tumor immunity remains unclear. Moral et al. show that a subset of tumor ILCs (TILCs) may participate in an organ-specific immune response and can be unleashed by PD-1 blockers to sustain tumor-specific T cell responses.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Immunity, Innate
Lymphocytes*
Neoplasms*
Programmed Cell Death 1 Receptor
T-Lymphocytes

Substances

Programmed Cell Death 1 Receptor